Renal-limited thrombotic microangiopathy after switching from bevacizumab to ramucirumab: a case report
Abstract Background It is well known that vascular endothelial growth factor (VEGF) inhibitors can cause proteinuria. The incidence of proteinuria is high for bevacizumab, a humanized monoclonal antibody directed against VEGF, but the range of proteinuria rarely becomes nephrotic (2.2% occurrence ac...
Main Authors: | Ryo Yamada, Takao Okawa, Ken Matsuo, Makoto Suzuki, Noriko Mori, Kiyoshi Mori |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-01-01
|
Series: | BMC Nephrology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12882-018-1194-9 |
Similar Items
-
Renal-Limited Thrombotic Microangiopathy due to Bevacizumab Therapy for Metastatic Colorectal Cancer: A Case Report
by: Naoya Toriu, et al.
Published: (2019-06-01) -
Nintedanib-Induced Renal Thrombotic Microangiopathy
by: Takeshi Fujita, et al.
Published: (2021-07-01) -
Sunitinib induced nephrotic syndrome and thrombotic microangiopathy
by: P K Jha, et al.
Published: (2013-01-01) -
Thrombotic microangiopathy in the era of HIV
by: Davies, Malcolm
Published: (2014) -
Reversible renal-limited thrombotic microangiopathy due to gemcitabine-dexamethasone-cisplatin therapy: a case report
by: Masashi Nishikubo, et al.
Published: (2021-05-01)